UNSPSC 51162739: Stepronin

This classification denotes a mucolytic agent with the molecular formula C10H11NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 0NOY894QRB, chemically known as glycine, n-(1-oxo-2-((2-thienylcarbonyl)thio)propyl)- but more generally known as stepronin, which bears US NIH Compound Identifier 54120. European Medicines Agency schedules Stepronin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10645MIG. The term STEPRONIN is an International Non-Proprietary Name.

UNSPSC 51162739 Stepronin, a Commodity code, covers pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter medications that state and local health agencies procure for community health programs, emergency response, and facility distribution. State and local issuers under this code include county health departments, state pharmaceutical purchasing cooperatives, and multistate cooperative purchasing alliances. Seminole County, Florida and the Minnesota Department of Administration's Office of State Procurement (administering the Minnesota Multistate Cooperative Purchasing Alliance) are recent active buyers.

Activity under the code spans Florida and Minnesota, with recent solicitations addressing distinct procurement paths. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year contract with one-year renewal option, with quarterly deliveries to its Community Health Building in Sanford; the IFB closed July 26, 2023. The Minnesota Department of Administration issued RFP S1070000015802 in January 2026 through MMCAP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring manufacturers to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Both solicitations require vendors to maintain workers' compensation and general liability insurance, comply with FDA and Drug Supply Chain Security Act requirements, and meet E-Verify and drug-free workplace certification standards.